|
Adenocarcinoma of lung (disorder)
|
0.300 |
Biomarker
|
disease |
CTD_human |
c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.
|
27602772 |
2016 |
|
Intermittent Claudication
|
0.200 |
Therapeutic
|
phenotype |
RGD |
Next, we explored the therapeutic effects of int6 siRNA injected into the adductor magnus muscle on IC.
|
21771896 |
2011 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Alopecia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic prediction of male pattern baldness.
|
28196072 |
2017 |
|
Dupuytren Contracture
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis.
|
28886342 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, INT6/eIF3e is a double-edged sword that has both oncogenic and tumor suppressive abilities.
|
27814599 |
2017 |
|
Other alopecia
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk.
|
29146897 |
2017 |
|
Androgenetic Alopecia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk.
|
29146897 |
2017 |
|
Alopecia, Androgenetic, 3
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk.
|
29146897 |
2017 |
|
Alopecia, Androgenetic, 2
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk.
|
29146897 |
2017 |
|
Alopecia, Androgenetic, 1
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk.
|
29146897 |
2017 |
|
Alopecia, Male Pattern
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk.
|
29146897 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The high expression of eIF3e in colon cancer was significantly correlated with tumor size (P < 0.001), lymph node involvement (P < 0.001), distant metastasis (P < 0.001), clinical stage (P < 0.001), histopathologic classification (P < 0.001), and vessel invasion (P = 0.036).
|
25400724 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our data indicate a novel role of eIF3e/Int6 in the regulation of EMT in breast epithelial cells and support a tumor suppressor role of eIF3e/Int6.
|
22907435 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the current study, we investigate the role of the tumor suppressor Int6/eIF3e in the regulation of the expression of angiogenic factors in neuronal cells.
|
22960363 |
2012 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE.
|
21379329 |
2011 |
|
Dupuytren Contracture
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Wnt signaling and Dupuytren's disease.
|
21732829 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of fatty acid binding protein 5 (FABP5), poly(A) binding protein cytoplasmic 1 (PABPC1), DEAD box polypeptide 5 (DDX5), splicing factor 3b subunit 1 (SF3B1), murine mammary tumour integration site 6 (EIF3S6), tropomyosin 2β (TPM2), transgelin (TAGLN) and cyclin-dependent kinase-associated protein (Cks2) genes was measured in bladder samples using real-time reverse transcription-polymerase chain reaction.
|
21672358 |
2011 |
|
Dupuytren's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Wnt signaling and Dupuytren's disease.
|
21732829 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Only 4% of WapInt6sh non-breeding females developed tumors by 2 years of age.
|
17626637 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To address this discrepancy and identify HIF-2 alpha-specific target genes, we performed yeast two-hybrid analysis and identified the tumor suppressor Int6/eIF3e/p48 as a novel target gene product involved in HIF-2 alpha regulation.
|
17324924 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, EIF2S6/Int-6, which was originally identified as a common integration site for the mouse mammary tumour virus in virally induced mouse mammary tumours, is a candidate breast cancer susceptibility gene because of its putative role in maintaining chromosome stability.
|
17187232 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In 85% of the tumors with reduced Int6 expression, the transcription promoter and first exon were hypermethylated, whereas only 4% of the tumors with elevated Int6 RNA levels were hypermethylated (P <0.000001).
|
15867213 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additional studies on larger series of tumor specimens with long-term follow-up are needed to determine whether Int-6/eIF3-p48 expression may represent a new prognostic or predictive marker.
|
11115556 |
2001 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Loss of heterozyosity (LOH) was detected in 11 of 39 (28%) of the tumor samples informative for a polymorphic sequence in intron 7 of INT6.
|
9403073 |
1997 |